Sfoglia per Autore  

Opzioni
Mostrati risultati da 41 a 60 di 178
Titolo Data di pubblicazione Autore(i) File
A long term, non-tumorigenic rat hepatocyte cell line and its malignant counterpart, as tools to study hepatocarcinogenesis 2017 Angioni, Maria Maddalena; Bellofatto, Kevin; Merlin, Simone; Menegon, Silvia; Perra, Andrea; Petrelli, Annalisa; Sulas, Pia; Giordano, Silvia; Columbano, Amedeo; Follenzi, Antonia
YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC 2017 Ghiso, Elena*; Migliore, Cristina; Ciciriello, Vito; Morando, Elena; Petrelli, Annalisa; Corso, Simona; De Luca, Emmanuele; Gatti, Gaia; Volante, Marco; Giordano, Silvia
Targeted therapies for gastric cancer: failures and hopes from clinical trials 2017 Apicella, Maria; Corso, Simona; Giordano, Silvia
Istologia Medica 2016 Saverio Cinti, Michelangelo Cordenonsi, Simona Corso, Ottavio Cremona, Massimo De Felici, Roberta Di Pietro, Nicoletta Gagliano, Silvia Giordano, Nadir M. Maraldi, Carla Martinelli, Alessandro Moretta, Sergio Morini, Beatrice Nico, Maria Prat, Domenico Ruzzolo, Domenico Ribatti, Giovanni Francesco Spatola, Carlo Tacchetti
The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival 2016 Mattu, Sandra; Fornari, Francesca; Quagliata, Luca; Perra, Andrea; Angioni, Maria Maddalena; Petrelli, Annalisa; Menegon, Silvia; Morandi, Andrea; Chiarugi, Paola; Ledda-Columbano, Giovanna Maria; Gramantieri, Laura; Terracciano, Luigi; Giordano, Silvia; Columbano, Amedeo
Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis 2016 Kowalik, Marta Anna; Guzzo, Giulia; Morandi, Andrea; Perra, Andrea; Menegon, Silvia; Masgras, Ionica; Trevisan, Elena; Angioni, Maria Maddalena; Fornari, Francesca; Quagliata, Luca; Ledda-Columbano, Giovanna Maria; Gramantieri, Laura; Terracciano, Luigi; Giordano, Silvia; Chiarugi, Paola; Rasola, Andrea; Columbano, Amedeo
How Can Gastric Cancer Molecular Profiling Guide Future Therapies? 2016 Corso, Simona; Giordano, Silvia
MiRs*: Innocent bystanders only? 2016 Giordano, Silvia
The Dual Roles of NRF2 in Cancer 2016 Menegon, Silvia; Columbano, Amedeo; Giordano, Silvia
Growth Factor Receptors 2015 Silvia Giordano, Carla Boccaccio, Paolo M. Comoglio
Cytokeratin-19 positivity is acquired along cancer progression and does not predict cell origin in rat hepatocarcinogenesis 2015 Kowalik, Marta Anna; Sulas, Pia; Ledda-Columbano, Giovanna Maria; Giordano, Silvia; Columbano, Amedeo; Perra, Andrea
Nrf2, but not β-catenin, mutation represents an early event in rat hepatocarcinogenesis. 2015 Zavattari P;Perra A;Menegon S;Kowalik MA;Petrelli A;Angioni MM;Follenzi A;Quagliata L;Ledda-Columbano GM;Terracciano L;Giordano S;Columbano A
By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy. 2015 Petrelli, A; Carollo, R; Cargnelutti, M; Iovino, F; Callari, M; Cimino, D; Todaro, M; Mangiapane, Lr; Giammona, A; Cordova, A; Montemurro, F; Taverna, D; Daidone, Mg; Stassi, G; Giordano, S.
Local hypothyroidism favours the progression of rat preneoplastic lesions to HCC. 2014 Frau C;Loi R;Petrelli A;Perra A;Menegon S;Kowalik MA;Pinna S;Leoni VP;Fornari F;Gramantieri L;Ledda-Columbano GM;Giordano S;Columbano A
Activation of RAS family members confers resistance to ROS1 targeting drugs. 2014 Cargnelutti M;Corso S;Pergolizzi M;Mévellec L;Aisner DL;Dziadziuszko R;Varella-Garcia M;Comoglio PM;Doebele RC;Vialard J;Giordano S
Targeted therapies in cancer and mechanisms of resistance. 2014 Corso S;Giordano S
YAP activation is an early event and a potential therapeutic target in liver cancer development. 2014 Perra A;Kowalik MA;Ghiso E;Ledda-Columbano GM;Di Tommaso L;Angioni MM;Raschioni C;Testore E;Roncalli M;Giordano S;Columbano A
MicroRNA/gene profiling unveils early molecular changes and NRF2 activation in a rat model recapitulating human HCC. 2014 Petrelli A;Perra A;Cora D;Sulas P;Menegon S;Manca C;Migliore C;Kowalik MA;Ledda-Columbano GM;Giordano S;Columbano A
Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence. 2014 Martin V;Corso S;Comoglio PM;Giordano S
Met as a therapeutic target in HCC: Facts and hopes. 2013 Giordano S; Columbano A.
Mostrati risultati da 41 a 60 di 178
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile